信迪利单抗联合安罗替尼一线治疗晚期NSCLC的1b期研究
该1b期研究评估信迪利单抗联合安罗替尼一线治疗无EGFR/ALK/ROS1突变的晚期NSCLC患者,共22例,客观缓解率72.7%,疾病控制率100%,中位无进展生存期15个月,≥3级治疗相关不良事件发生率54.5%。
要点
- 信迪利单抗联合安罗替尼一线治疗晚期NSCLC客观缓解率达72.7%。
- 中位无进展生存期15个月,12个月无进展生存率71.4%。
- ≥3级治疗相关不良事件发生率54.5%,以3级高血压为主。
核心结论
- 信迪利单抗联合安罗替尼一线治疗晚期NSCLC显示出令人鼓舞的疗效、持久性和安全性,代表一种新型无化疗方案。
研究设计与样本
- 1b期试验(NCT03628521),纳入治疗初治、不可切除IIIC/IV期且无EGFR/ALK/ROS1突变的NSCLC患者,共22例接受信迪利单抗200mg第1天联合安罗替尼12mg第1-14天,每3周一次直至疾病进展或不可耐受毒性。
主要发现
- 中位随访15.8个月(范围8.3-19.3),中位无进展生存期15个月(95%CI 8.3个月-未达到),12个月无进展生存率71.4%(95%CI 47.2%-86.0%)。
- ≥3级治疗相关不良事件发生率54.5%,以3级高血压为主(2/22,9.1%),无4级治疗相关不良事件,发生1例5级免疫相关性肺炎。
临床怎么用
- 对于无EGFR/ALK/ROS1突变的晚期NSCLC初治患者,信迪利单抗联合安罗替尼可作为潜在的无化疗一线选择,但需关注高血压和免疫相关性肺炎等不良反应。
局限性
- 样本量较小(22例),为单臂1b期研究,随访时间有限,结论需更大样本随机对照试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Although the interaction between tumor immune microenvironment and angiogenesis has been well established, evidence supporting the chemo-free combination of immune checkpoint inhibitors plus antiangiogenic tyrosine kinase inhibitors in treatment-naive patients with advanced NSCLC is insufficient. This report provides the efficacy and safety of sintilimab combined with anlotinib as first-line therapy for advanced NSCLC from a phase 1b trial (NCT03628521). METHODS: Eligible patients who were treatment-naive and had unresectable stage IIIB/C or IV NSCLC without EGFR/ALK/ROS1 mutations received sintilimab (200 mg, day 1) and anlotinib (12 mg, day 1-14) every 3 weeks till disease progression or unacceptable toxicity. Baseline programmed death-ligand 1 expression and tumor mutation burden status was assessed in all patients. The primary end points were objective response rate and safety. RESULTS: A total of 22 patients received sintilimab and anlotinib. Median follow-up was 15.8 months (range: 8.3-19.3). Sixteen patients achieved confirmed partial response with an objective response rate of 72.7% (95% confidence interval [CI]: 49.8%-89.3%) and disease control rate of 100% (95% CI: 84.6%-100%). Median progression-free survival was 15 months (95% CI: 8.3 m, not reached), and the 12-month progression-free survival rate was 71.4% (95% CI: 47.2%-86.0%). The incidence rate of grade 3 or higher treatment-related adverse events was 54.5%, and grade 3 hypertension was predominant (two of 22, 9.1%). No grade 4 treatment-related adverse events were observed, and one case of grade 5 immune-related pneumonitis occurred. CONCLUSIONS: To the best of our knowledge, this is the first study that assessed an anti-programmed cell death protein 1 antibody combined with a multitarget antiangiogenic tyrosine kinase inhibitor in the frontline setting for patients with NSCLC. In view of its encouraging efficacy, durability, and safety profile, sintilimab plus anlotinib represents a novel chemotherapy-free regimen in this patient population.
引用
- Chu T, Zhong R, Zhong H, et al. Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC. J Thorac Oncol. 2021. PMID: 33524601. doi:10.1016/j.jtho.2020.11.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。